

Bravoxin

Authorised

- Clostridium novyi, type D, toxoid
- Clostridium sordellii, toxoid
- Tetanus toxoid adsorbed
- Clostridium septicum, toxoid
- Clostridium novyi, toxoid
- Clostridium chauvoei, Inactivated
- Clostridium perfringens, type D, epsilon toxoid
- Clostridium perfringens, type B and C, beta toxoid
- Clostridium perfringens, type A, alpha toxoid

Product identification

Medicine name:

Bravoxin

Tribovax vet. injeksjonsvæske, suspensjon til storfe og sau

Active substance:

Clostridium novyi, type D, toxoid

Clostridium sordellii, toxoid

Tetanus toxoid adsorbed

Clostridium septicum, toxoid

Clostridium novyi, toxoid

Clostridium chauvoei, Inactivated

Clostridium perfringens, type D, epsilon toxoid

Clostridium perfringens, type B and C, beta toxoid

Clostridium perfringens, type A, alpha toxoid

Target species:

Cattle
Sheep

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Clostridium novyi, type D, toxoid
17.40 enzyme-linked immunosorbent assay unit / 1.00 millilitre(s)
Clostridium sordellii, toxoid
4.40 enzyme-linked immunosorbent assay unit / 1.00 millilitre(s)
Tetanus toxoid adsorbed
4.90 enzyme-linked immunosorbent assay unit / 1.00 millilitre(s)
Clostridium septicum, toxoid
4.60 enzyme-linked immunosorbent assay unit / 1.00 millilitre(s)
Clostridium novyi, toxoid
3.80 enzyme-linked immunosorbent assay unit / 1.00 millilitre(s)
Clostridium chauvoei, Inactivated
90.00 percentage protection / 1.00 millilitre(s)
Clostridium perfringens, type D, epsilon toxoid
5.30 enzyme-linked immunosorbent assay unit / 1.00 millilitre(s)
Clostridium perfringens, type B and C, beta toxoid
18.20 enzyme-linked immunosorbent assay unit / 1.00 millilitre(s)
Clostridium perfringens, type A, alpha toxoid
0.50 enzyme-linked immunosorbent assay unit / 1.00 millilitre(s)

Pharmaceutical form:

Suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

-

Cattle

- Meat and offal. 0 day
- Milk. 0 day

-

Sheep

- Meat and offal. 0 day
- Milk. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI02AB01

QI04AB01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Norway

Package description:

(ID3): 1 Box with 1 Bottle (Low Density PolyEthylene) with 100 millilitre(s) (100.0 millilitre(s))

(ID2): 1 Box with 1 Bottle (Low Density PolyEthylene) with 50 millilitre(s) (50.0 millilitre(s))

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Intervet International B.V.

Marketing authorisation date:

16/07/2021

Manufacturing sites for batch release:

Intervet International B.V.

Responsible authority:

Norwegian Medical Products Agency

Authorisation number:

20-13624

Date of authorisation status change:

16/07/2021

Reference member state:

Germany

Procedure number:

DE/V/0289/001

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland
France Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg
Netherlands Norway Poland Portugal Romania Slovakia Spain Sweden
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)

Published on: 14/02/2022

[Download](#)

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents

Source URL: <https://medicines.health.europa.eu/veterinary/600000063212>